With negative FDA panel vote, AstraZeneca may look at narrow Lynparza nod in prostate cancer

A panel of external experts for the FDA voted 11 to 1 in support of a narrow approval for AstraZeneca and Merck’s Lynparza, used in tandem with Johnson & Johnson’s Zytiga and a corticosteroid, | A panel of external experts for the FDA voted 11 to 1 in support of a narrow approval for AstraZeneca…#fda #astrazeneca #merck #lynparza #johnsonjohnsons #zytiga #mcrpc #rickpazdur
Source: Reuters: Health - Category: Consumer Health News Source Type: news